Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
28.48
+0.10 (+0.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
937,524
Open
28.34
Bid (Size)
27.86 (1)
Ask (Size)
30.01 (1)
Prev. Close
28.38
Today's Range
28.17 - 28.56
52wk Range
24.53 - 41.58
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
What 8 Analyst Ratings Have To Say About Genmab
July 15, 2024
Via
Benzinga
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
July 15, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Performance
YTD
-11.30%
-11.30%
1 Month
+14.61%
+14.61%
3 Month
-0.32%
-0.32%
6 Month
+0.67%
+0.67%
1 Year
-31.14%
-31.14%
More News
Read More
NASDAQ:GMAB, an undervalued stock with good fundamentals.
July 01, 2024
Via
Chartmill
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
June 28, 2024
From
Genmab A/S
Via
Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
June 27, 2024
Via
Benzinga
Exposures
Product Safety
10 Analysts Assess Genmab: What You Need To Know
June 20, 2024
Via
Benzinga
What 9 Analyst Ratings Have To Say About Genmab
May 20, 2024
Via
Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
May 02, 2024
Via
Chartmill
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
June 26, 2024
From
Genmab A/S
Via
Business Wire
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
Via
InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
June 21, 2024
Via
Chartmill
7 Stocks That Could Safely 10X by 2030
June 06, 2024
Via
InvestorPlace
Decoding 9 Analyst Evaluations For Genmab
April 30, 2024
Via
Benzinga
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 03, 2024
From
Genmab A/S
Via
Business Wire
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
June 02, 2024
From
Genmab A/S
Via
Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
Genmab A/S
Via
Business Wire
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 24, 2024
Via
Benzinga
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Genmab A/S
Via
Business Wire
Genmab Completes Acquisition of ProfoundBio
May 21, 2024
From
Genmab A/S
Via
Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Via
InvestorPlace
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14, 2024
From
Genmab A/S
Via
Business Wire
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Genmab A/S
Via
Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Pfizer Inc.
Via
Business Wire
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.